About Orthofix (NASDAQ:OFIX)
Orthofix International N.V., a medical device company, provides musculoskeletal healing products and value-added services worldwide. It operates through four segments: BioStim, Extremity Fixation, Spine Fixation, and Biologics. The BioStim segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion and are indicated as treatment to enhance fusion success rates in cervical and lumbar spine, as well as a therapeutic treatment for non-spine fractures. The Extremity Fixation segment designs, develops, and markets orthopedic products used in fracture repair, deformity correction, and bone reconstruction procedures. The Spine Fixation segment designs, develops, and markets a portfolio of implant products used in surgical procedures of the spine. The Biologics segment provides a portfolio of regenerative products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. Orthofix International N.V. was founded in 1987 and is headquartered in Lewisville, Texas.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:OFIX
CUSIPN6748L10
Phone599-9-4658525
Debt
Debt-to-Equity RatioN/A
Current Ratio3.17%
Quick Ratio2.15%
Price-To-Earnings
Trailing P/E Ratio36.11
Forward P/E Ratio31.99
P/E Growth3.31
Sales & Book Value
Annual Sales$433.82 million
Price / Sales2.50
Cash Flow$2.8380 per share
Price / Cash20.74
Book Value$16.23 per share
Price / Book3.63
Profitability
EPS (Most Recent Fiscal Year)$1.62
Net Income$6.22 million
Net Margins1.43%
Return on Equity10.66%
Return on Assets7.93%
Miscellaneous
Employees858
Outstanding Shares18,410,000
Orthofix (NASDAQ:OFIX) Frequently Asked Questions
What is Orthofix's stock symbol?
Orthofix trades on the NASDAQ under the ticker symbol "OFIX."
How were Orthofix's earnings last quarter?
Orthofix (NASDAQ:OFIX) issued its quarterly earnings data on Monday, February, 26th. The medical device company reported $0.52 EPS for the quarter, beating the Zacks' consensus estimate of $0.50 by $0.02. The medical device company had revenue of $116.90 million for the quarter, compared to analysts' expectations of $116.93 million. Orthofix had a net margin of 1.43% and a return on equity of 10.66%. The firm's revenue was up 7.7% on a year-over-year basis. During the same period in the prior year, the company earned $0.42 EPS. View Orthofix's Earnings History.
When is Orthofix's next earnings date?
What guidance has Orthofix issued on next quarter's earnings?
Orthofix issued an update on its FY18 earnings guidance on Monday, February, 26th. The company provided earnings per share (EPS) guidance of $1.76-1.84 for the period, compared to the Thomson Reuters consensus estimate of $1.83. The company issued revenue guidance of $450-455 million, compared to the consensus revenue estimate of $452.35 million.
What price target have analysts set for OFIX?
6 analysts have issued 12-month price targets for Orthofix's stock. Their predictions range from $53.25 to $67.00. On average, they expect Orthofix's share price to reach $56.90 in the next year. View Analyst Ratings for Orthofix.
Who are some of Orthofix's key competitors?
Some companies that are related to Orthofix include Mazor Robotics (MZOR), Irhythm Technologies (IRTC), Intersect ENT (XENT), ATRION (ATRI), OraSure Technologies (OSUR), Glaukos (GKOS), Luminex (LMNX), K2M Group (KTWO), MiMedx Group (MDXG), LeMaitre Vascular (LMAT), CryoLife (CRY), Cardiovascular Systems (CSII), AtriCure (ATRC), AngioDynamics (ANGO), Cerus (CERS), Anika Therapeutics (ANIK), Tactile Systems Technology (TCMD) and SurModics (SRDX).
Who are Orthofix's key executives?
Orthofix's management team includes the folowing people:
- Mr. Bradley R. Mason, Pres, CEO & Director (Age 64)
- Mr. Doug Rice, CFO & Chief Accounting Officer (Age 52)
- Mr. Michael M. Finegan, Chief Strategy Officer (Age 54)
- Mr. Bradley V. Niemann, Pres of BioStim Bus. (Age 48)
- Mr. Davide Bianchi, Pres of Global Extremity Fixation (Age 53)
Has Orthofix been receiving favorable news coverage?
News stories about OFIX stock have trended somewhat positive on Monday, Accern reports. The research firm identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Orthofix earned a news sentiment score of 0.19 on Accern's scale. They also assigned media stories about the medical device company an impact score of 42.41 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.
How do I buy shares of Orthofix?
Shares of OFIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Orthofix's stock price today?
One share of OFIX stock can currently be purchased for approximately $58.86.
How big of a company is Orthofix?
Orthofix has a market capitalization of $1.08 billion and generates $433.82 million in revenue each year. The medical device company earns $6.22 million in net income (profit) each year or $1.62 on an earnings per share basis. Orthofix employs 858 workers across the globe.
How can I contact Orthofix?
Orthofix's mailing address is 7 ABRAHAM DE VEERSTRAAT, WILLEMSTAD P8, . The medical device company can be reached via phone at 599-9-4658525 or via email at [email protected]
MarketBeat Community Rating for Orthofix (OFIX)
MarketBeat's community ratings are surveys of what our community members think about Orthofix and other stocks. Vote "Outperform" if you believe OFIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OFIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Orthofix (NASDAQ:OFIX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Orthofix in the last 12 months. Their average twelve-month price target is $56.90, suggesting that the stock has a possible downside of 3.33%. The high price target for OFIX is $67.00 and the low price target for OFIX is $53.25. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $56.90 | $56.90 | $53.30 | $52.50 |
| Price Target Upside: | 3.33% downside | 1.34% upside | 6.92% upside | 10.88% upside |
Orthofix (NASDAQ:OFIX) Consensus Price Target History
Orthofix (NASDAQ:OFIX) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Orthofix (NASDAQ:OFIX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Orthofix (NASDAQ OFIX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 95.14%
Orthofix (NASDAQ OFIX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/11/2017 | Bradley V Niemann | Insider | Sell | 5,547 | $52.08 | $288,887.76 | 34,631 |  |
| 11/28/2017 | Brad Mason | CEO | Sell | 5,000 | $53.48 | $267,400.00 | 183,053 | |
| 11/6/2017 | Luke T Faulstick | Director | Sell | 4,800 | $51.22 | $245,856.00 | 7,729 | |
| 9/11/2017 | Bradley V Niemann | Insider | Sell | 6,956 | $49.44 | $343,904.64 | 40,178 | |
| 9/11/2017 | Rice Doug | CFO | Sell | 7,353 | $49.46 | $363,679.38 | 44,743 | |
| 8/21/2017 | Brad Mason | CEO | Sell | 2,733 | $48.10 | $131,457.30 | 188,053 | |
| 8/10/2017 | Raymond Fujikawa | Insider | Sell | 6,364 | $47.06 | $299,489.84 | 31,084 | |
| 11/10/2016 | Brad Mason | CEO | Sell | 9,538 | $36.83 | $351,284.54 | 151,219 | |
| 9/1/2016 | Michael Finegan | Insider | Sell | 25,000 | $45.16 | $1,129,000.00 | 51,670 | |
| 6/10/2016 | Maria Sainz | Director | Sell | 4,157 | $46.33 | $192,593.81 | 20,828 | |
| 6/9/2016 | Brad Mason | CEO | Sell | 18,336 | $46.00 | $843,456.00 | 160,256 | |
| 6/8/2016 | Bradley V Niemann | Insider | Sell | 3,402 | $44.70 | $152,069.40 | 25,500 | |
| 5/20/2016 | Robert Allen Goodwin II | Insider | Sell | 13,187 | $44.00 | $580,228.00 | 39,607 | |
| 4/18/2016 | Michael Finegan | Insider | Sell | 80,972 | $42.71 | $3,458,314.12 | 90,996 | |
| 11/11/2015 | Michael Finegan | Insider | Sell | 14,140 | $42.00 | $593,880.00 | 58,252 | |
| 11/6/2015 | Brad Mason | CEO | Sell | 15,018 | $40.60 | $609,730.80 | 140,256 | |
| 11/6/2015 | Jeffrey Schumm | insider | Sell | 15,000 | $40.67 | $610,050.00 | 68,882 | |
| 6/2/2015 | Ronald A Matricaria | Director | Buy | 50,000 | $32.65 | $1,632,500.00 | | |
| 5/21/2015 | James F Hinrichs | Director | Buy | 10,000 | $33.17 | $331,700.00 | | |
| 6/10/2014 | Mark A Heggestad | CFO | Buy | 13,696 | $33.25 | $455,392.00 | | |
| 5/17/2013 | Brad Mason | CEO | Buy | 5,000 | $26.45 | $132,250.00 | | |
| 5/17/2013 | Kenneth R Weisshaar | Director | Buy | 1,000 | $26.40 | $26,400.00 | | |
| 5/14/2013 | James Gero | Director | Buy | 20,000 | $26.37 | $527,400.00 | | |
| 2/27/2013 | Robert S Vaters | CEO | Buy | 3,000 | $35.97 | $107,910.00 | | |
(Data available from 1/1/2013 forward)
Orthofix (NASDAQ OFIX) News Headlines
| Source: |
|
Orthofix (NASDAQ:OFIX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Orthofix (NASDAQ:OFIX) Income Statement, Balance Sheet and Cash Flow Statement
Orthofix (NASDAQ OFIX) Stock Chart for Monday, April, 23, 2018
Loading chart…
